| INTRODUCTION
The PI3K pathway plays an important role in many cellular processes, including cell proliferation, differentiation, and survival.
1,2 The PI3K pathway is also involved in neoplastic transformations through mutation of one or more key molecules, including the class I isomers of the PI3K family (subunits p110a, p110b, p110c, and p110d). 1 The PI3K/Akt/mammalian target of rapamycin (mTOR) pathway, which is downstream of the ER, is hyperactivated in patients who do not respond to ER-targeting therapy, 3 and mutations in the PIK3CA gene are frequent. 1 Mutations in p110a coding regions of the PIK3CA
gene, so-called PI3Ka isoforms, are established in several solid tumors, and are particularly prevalent in cervical cancer, squamous cell lung cancer, head and neck cancer, and breast cancer. 1 Therefore, small molecule inhibitors that target the PI3K pathway may provide clinical benefit in patients with these cancers.
Taselisib is an isoform-selective PI3K inhibitor that shows potent inhibitory activity against p110a, p110d, and p110c, but is~30fold less potent against the p110b isoform. 4 Preclinical studies have indicated that taselisib has increased antitumor activity in several PIK3CA-mutated tumor models, including uterine serous carcinoma, 5 head and neck squamous carcinoma, 4 and breast cancer. 6 Breast cancer is the most common cancer diagnosed in women. In 2012, the estimated number of new breast cancer cases in women comprised 25% of all new cancer cases worldwide. 7 Breast cancer is also the leading cause of death in women, accounting for 14.7% of the total deaths from cancer in 2012. 7 Advances in endocrine therapy have resulted in the prolongation of both disease-free and overall survival for those patients with ER-positive (ER+) breast tumors; however, although 5-year recurrence rates have been significantly reduced with endocrine therapy, 5-year mortality rates have not decreased to the same degree. 8 In addition, the response to endocrine agents is heterogeneous and 40%-50% of patients with ER+ tumors can relapse in the adjuvant setting. 9 Prognosis of advanced/recurrent breast cancer is poor, with 5% of patients having PFS 10 years post-first chemotherapy dose. 10, 11 Maintaining quality of life in these patients is an important part of their treatment, and therapeutic agents should be specific for relevant molecular targets and be used to treat appropriate patient populations in order to reduce AE.
This article presents the results of a phase I dose-escalation study conducted in Japan, which was designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of taselisib monotherapy in patients with advanced solid tumors, and taselisib as part of combination therapy in patients with HR-positive locally advanced or recurrent breast cancer. Patients were excluded from any stage of the study if they had previous hypersensitivity to the excipients in taselisib tablets, diabetes mellitus requiring medication, central nervous system metastases, non-infectious bowel inflammation, or severe uncontrolled systemic cardiac, lung, or liver disease. Patients were also excluded from stage 2 of the study if they had received 2 or more previous chemotherapy regimens for advanced or recurrent breast cancer, had experienced previous hypersensitivity to components of fulvestrant, or had more than 1 primary cancer with a disease-free interval of less than 5 years. The PIK3CA mutation was detected by using an archived sample from the primary or recurrent tumor at the local site. In both stages of the study, patients continued treatments until intolerable toxicity, PD, or withdrawal of consent.
| MATERIALS AND METHODS

| Study design
| Study treatments
| Outcomes
Primary objectives of the present study were to evaluate the safety (including determining any DLT) and pharmacokinetics of taselisib.
DLT were set as determination factors to decide whether or not to proceed to the next cohort, and were defined as taselisib-related and 24 hours after dose on day 15, during cycle 2 and cycle 6 at predose on day 1, and on the last day of the study ( Figure 2 ). Concentration of taselisib was determined using a validated liquid chromatography-tandem mass spectrometry analytical procedure, with a lower limit of quantification of 0.05 ng/mL.
The secondary objective of the study was to determine the preliminary efficacy of taselisib in both stages of the study. Efficacy was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 13 Assessment of lesions in stage 1 was conducted before the start of the study.
| Statistical analysis
In both stages of the study, all statistical analyses were descriptive in nature; thus, no formal hypothesis testing was conducted. Efficacy was analyzed in the full analysis set, which comprised all patients who received at least 1 dose of study treatment. Safety was analyzed in the safety population, which comprised all patients who received at least 1 dose of treatment. All statistical analyses were carried out using SAS, version 9.2 (SAS Institute, Cary, NC, USA).
3 | RESULTS
| Participants
This study was conducted between 21 August 2014 and 17 May 2017. Overall, 9 patients were included in stage 1 and 6 patients were included in stage 2. Baseline characteristics of patients included in both stages of the study are reported in Table 1 . In stage 1, all patients had a baseline ECOG PS of 0. PIK3CA mutations were found in 3 patients, including 1 PIK3CA E542K mutation and 2 PIK3CA H1047R mutations. In stage 2, 2 patients had baseline ECOG PS 1. PIK3CA mutations were found in 2 patients. corticosteroid. All of these SAE were considered treatment-related.
| Safety
| Pharmacokinetics
In stage 1, single and multiple oral doses of taselisib were rapidly absorbed with a t max ranging from 0.483 to 8.00 hours (Table 3) .
Plasma concentration of taselisib gradually declined, with a t 1/2 of 12.9-32.0 hours. Linearity was observed after both single and multiple doses of taselisib and no accumulation was found for multiple doses beyond the level estimated by the single dose ( Figure 3 ). In stage 2, after single and multiple oral doses of taselisib plus fulvestrant 500 mg, taselisib was rapidly absorbed with a t max ranging from 0.933 to 4.07 hours; similar to the pharmacokinetics observed in stage 1 of the study, the plasma concentration of taselisib then gradually declined, with a t 1/2 of 16.1-26.5 hours (Table 3 ; Figure 3 ).
| Efficacy
In stage 1, all 9 patients had target lesions and were eligible for assessment per RECIST 1.1 after starting taselisib treatment. Three
T A B L E 1 Baseline characteristics of patients included in both stages of the present study Prior chemotherapy regimens, n (%) and a disease control rate of 100% (6/6; Figure 5 ). The 1 patient who achieved PR was positive for PIK3CA mutation (Figure 5) , and the duration of response in this patient was 613 days. PFS was 110-884 days in stage 2.
| DISCUSSION
This 3 + 3 dose-escalation study aimed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of taselisib as monotherapy and in combination with fulvestrant in Japanese patients. Overall, the results showed good safety and preliminary efficacy. The results from stage 1 suggested that taselisib had good tolerability, with the common treatment-related AE being diarrhea, rash, stomatitis, headache, and decreased appetite; these were consistent with AE seen in the previous taselisib global Phase I study 14 and studies of other PI3K inhibitors. [15] [16] [17] [18] All treatment-related SAE resolved or improved with dosage reduction, interruption, or discontinuation of treatment. Taselisib monotherapy was associated with 2 PR, all of which were in patients with PIK3CA-mutated tumors.
Regarding the pharmacokinetics of taselisib monotherapy, taselisib was rapidly absorbed and gradually declined. Single-dose AUC and C max were dose-proportional and t 1/2 was similar within the dose range of 2-6 mg. Dose proportionality was also observed in repeated doses. These results were consistent with the pharmacokinetics seen in the previous taselisib global Phase I study. 14 The t 1/2 of this study (range: 12.9-32.0 hours) was shorter than the t 1/2 obtained in the previous study 14 (mean: 36.7-43.8 hours) but this was because of the time points difference used for t 1/2 calculation. There was a shorter t 1/2 with repeated doses of taselisib monotherapy than with a single dose, although it should be noted that the t 1/2 for the single dose was calculated from the concentration from 0 to 72 hours, whereas the t 1/2 for the repeated dose was calculated from the concentration from 0 to 24 hours. Fulvestrant is a selective ER degrader, and has been shown to improve PFS in postmenopausal patients with advanced breast cancer. 19 Several studies of the combination of PI3K/Akt/mTOR inhibitors and fulvestrant have been completed (reviewed in 19 ), and these generally show improved PFS, but an increased level of toxicity occurred when pan-PI3K inhibitors (such as pictilisib and buparlisib)
were used in the combination. 19 It is reasonable to expect that a more specific PI3K inhibitor would have less toxicity, consistent with the manageable toxicity observed with taselisib in this small study.
There are some limitations associated with the present study that may affect interpretation of the results. In the previous taselisib study, 14 there was some indication that patients with PIK3CA mutations may have an increased response and, in the present study, the 3 PR were seen in patients with PIK3CA-mutated tumors; however, the small sample size of the present study and the unknown mutation status in the majority of patients means that the relationship between mutation status and efficacy cannot be completely determined. Based on the promising results of this study, further investigations into the safety, tolerability, and clinical efficacy of taselisib in larger patient populations are warranted.
In conclusion, this phase I study is the first study of taselisib tablet administration in Japanese patients. The data showed that taselisib has a good tolerability profile when given as monotherapy in doses up to 6 mg in patients with advanced solid tumors, and up to 4 mg in combination with fulvestrant when given to patients with HR-positive, HER2-negative advanced/recurrent breast cancer. PR were observed in 2 patients receiving taselisib monotherapy and in 1 patient receiving combination therapy. As all patients who had PR had PIK3CA-mutated tumors, taselisib is expected to be effective in patients with PIK3CA-mutated breast cancer.
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